Fig 1: Knockdown of LXRß expression blocks the synergistic effects of T0901317 on gefitinib in A549 cells. (A) Knockdown of LXRa and LXRß expression was validated by quantitative PCR. *P < 0.001 versus NC groups. (B) The effect of LXR knockdown on A549 cell proliferation was quantified by CCK8 assays. Cells were treated with 5 µm gefitinib alone or in combination with 5 µm T0901317 for 4 days. *P < 0.01, **P < 0.001 between two groups. (C, D) Western blot analysis was performed to detect the expression of AKT and p-AKT after A549 (C) and H1650 (D) cells were treated with 5 µm T0901317 for different days or increasing concentrations of T0901317 for 4 days.